From Medscape Psychiatry

Coverage from the

15th Clinical Trials on Alzheimer's Disease (CTAD) Conference

November 29 - December 02, 2022; San Francisco, California

November 29 - December 02, 2022 San Francisco, California

Conference News

CTAD 2022 Exercise to Prevent Cognitive Decline in MCI: New Data
Medscape Medical News, December 9, 2022
CTAD 2022 Antipsychotic Shows Benefit for Alzheimer's Agitation
Medscape Medical News, December 5, 2022
CTAD 2022 Personalized Approach to Alzheimer's Risk Factors Boosts Cognition
Medscape Medical News, December 5, 2022

CTAD 2022 Med Tied to Improved Cognition in Comorbid Depression, Dementia
Medscape Medical News, December 5, 2022
CTAD 2022 Odd Twist in Phase 3 Alzheimer's Trial for Novel Tau Inhibitor
Medscape Medical News, December 1, 2022
CTAD 2022 'Modest' Benefit for Lecanemab in AD, Adverse Events Common
Medscape Medical News, November 29, 2022

Medscape Psychiatry© WebMD, LLC

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Popular News from CTAD 2021

Multivitamins, but Not Cocoa, Tied to Slowed Brain Aging Taking a daily multivitamin for 3 years is associated with a 60% slowing of cognitive aging, with the effects especially pronounced in patients with cardiovascular disease, new research suggests.
Medscape Medical News, Nov 11, 2021
Blood Test May Detect Preclinical Alzheimer's Years in Advance A new blood test that identifies a variant of the protein P53 appears to predict Alzheimer's disease progression up to 6 years in advance of a clinical diagnosis, early research suggests.
Medscape Medical News, Nov 23, 2021
Gum Disease Bacteria a New Treatment Target for Alzheimer's? An oral agent used to stop gum disease suggests a "new treatment paradigm" for mild to moderate Alzheimer's disease, early research suggests.
Medscape Medical News, Nov 23, 2021

Related Coverage

Related Resource

Alzheimer Disease News & Perspectives